PDCD1 and melanoma: This implies that the major reduction in tumor growth shown by the SAM+anti-PD-1 treatment is associated with a larger pool of genes that are involved in a diverse array of molecular pathways, including downregulation of key tumorigenesis pathways of melanoma, MAPK, and tyrosine kinase–related pathways, which could not be inhibited by the monotherapy treatment.